Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04489771 · ClinicalTrials.gov registry record · Phase 2

A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

A Phase 2 study of Carcinoma, Renal Cell, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 2
Development phase
154
Enrollment target
20
Study locations

NCT04489771 is a Phase 2 study of Carcinoma, Renal Cell that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 154 participants, below the 279-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04489771, a Phase 2 study of Carcinoma, Renal Cell, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
154 participants
Enrollment target
20
Study locations

Study Summary

This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).

Conditions Studied

Carcinoma, Renal Cell

Interventions

  • DRUG Belzutifan

Study Locations (20)

Nebraska

  • Cancer Partners of Nebraska ( Site 0003) - Lincoln
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0012) - Omaha

New York

  • New York Oncology Hematology P.C ( Site 0028) - Albany
  • Roswell Park Cancer Institute ( Site 0038) - Buffalo

Tennessee

  • UT West Cancer Center ( Site 0032) - Germantown
  • Urology Associates ( Site 0015) - Nashville

Texas

  • University of Texas Southwestern Medical Center at Dallas ( Site 0004) - Dallas
  • Baylor Scott & White Medical Center - Temple ( Site 0013) - Temple

Virginia

  • Inova Schar Cancer Institute ( Site 0001) - Fairfax
  • Blue Ridge Cancer Care - Roanoke ( Site 0017) - Roanoke

District of Columbia

  • Georgetown University Medical Center ( Site 0002) - Washington D.C.

Florida

  • Univ of Miami- Sylvester Comprehensive Cancer Center ( Site 0023) - Miami

Kentucky

  • Norton Cancer Institute - St. Matthews ( Site 0025) - Louisville

Trial Details

FieldValue
Enrollment Target 154 participants
Start Date 2020-09-13
Est. Completion 2026-10-04
Phase Phase 2

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04489771

The ClinicalTrials.gov registry entry for NCT04489771 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 279-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (45% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which Belzutifan is the first listed.

NCT04489771 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Nebraska, New York, Tennessee.

Frequently Asked Questions

What is clinical trial NCT04489771 about?

NCT04489771 is a clinical study titled "A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)". This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective resp...

What is the current status of trial NCT04489771?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2020-09-13. Estimated completion is 2026-10-04.

What conditions does trial NCT04489771 study?

This clinical trial studies the following conditions: Carcinoma, Renal Cell.

What interventions are being tested in trial NCT04489771?

The interventions under investigation include: Belzutifan (DRUG).

Who is sponsoring clinical trial NCT04489771?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04489771 being conducted?

This trial has 20 study locations across District of Columbia, Florida, Kentucky, Maryland, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Renal Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Renal Cell

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.